Breast Cancer Res Treat (2017) 165:375–382 DOI 10.1007/s10549-017-4310-9 CLINICAL TRIAL A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2- ampliﬁed breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104) 1 2 2 1,3 • • • • Lori J. Goldstein Fengmin Zhao Molin Wang Ramona F. Swaby 4 1,5 6,7 4 • • • • Joseph A. Sparano Neal J. Meropol Kapil N. Bhalla Christine M. Pellegrino 1 8 9,10 11,12 • • • R. Katherine Alpaugh Carla I. Falkson Paula Klein George W. Sledge Received: 17 May 2017 / Accepted: 23 May 2017 / Published online: 16 June 2017 Springer Science+Business Media New York 2017 Abstract HER2-overexpressing metastatic breast cancer with tras- Purpose Suberoylanilide hydroxamic acid (SAHA; tuzumab-resistant progressive disease. vorinostat), a small molecule inhibitor of histone deacety- Methods In Phase I, the SAHA dose was modiﬁed in lase, attenuates signaling pathways known to confer tras- cohorts of 3–6 patients to ﬁnd the dose level at which 0 or 1 tuzumab resistance. A combination of SAHA and patients experienced a dose-limiting toxicity (DLT) during trastuzumab may be a promising strategy
Breast Cancer Research and Treatment – Springer Journals
Published: Jun 16, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera